Abstract Number: 2020 • ACR Convergence 2024
Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
Background/Purpose: Pegloticase is a pegylated recombinant uricase approved for treatment of chronic uncontrolled gout. Because of the development of anti-drug antibodies (ADA), persistent urate lowering…Abstract Number: 2023 • ACR Convergence 2024
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…Abstract Number: 2127 • ACR Convergence 2024
Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population
Background/Purpose: Serum uric acid (UA) has been postulated to play a role against bone loss due to antioxidant mechanisms. Some studies have shown association between…Abstract Number: 0278 • ACR Convergence 2024
Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study
Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…Abstract Number: 1085 • ACR Convergence 2024
Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
Background/Purpose: Tigulixostat is a potent and highly selective non-purine based xanthine oxidase inhibitor (XOi) being investigated for the management of hyperuricemia in patients with gout.…Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…Abstract Number: 1096 • ACR Convergence 2024
Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia
Background/Purpose: Hyperuricemia (HU) is considered the most important factor preceding Gout. Yet, only a portion of hyperuricemic people develop Gout. Using a machine learning modeling…Abstract Number: 1097 • ACR Convergence 2024
CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia
Background/Purpose: Asymptomatic hyperuricemia and gout are two clinical conditions associated with a high risk of cardiovascular events and mortality. Recent data suggest that the number…Abstract Number: 1098 • ACR Convergence 2024
Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study
Background/Purpose: The role of concurrent hyperuricemia as a cardiovascular risk factor in patients with chronic inflammatory arthritis (CIA) has yet to be studied. We aim…Abstract Number: 1100 • ACR Convergence 2024
Coronary Dual-Energy Computed Tomography for the Detection of Monosodium Urate Crystal Deposition in the Arteries of Individuals with and Without Gout (CORODECT): A Multi-Center Prospective Imaging Study
Background/Purpose: Prior dual-energy CT (DECT) studies have suggested that monosodium urate (MSU) crystals may be present in the coronary arteries of patients with gout. However,…Abstract Number: 1898 • ACR Convergence 2024
Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects
Background/Purpose: Disorders of glucose metabolism are well-known major contributors to morbidity and mortality. Elevated serum uric acid (SUA), a key precursor of gout attacks, is…Abstract Number: 2013 • ACR Convergence 2024
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
- 1
- 2
- 3
- …
- 8
- Next Page »